• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ergomed appoints Dr Dan Weng as CEO

Ergomed appoints Dr Dan Weng as CEO

June 23, 2017
CenterWatch Staff

Ergomed, a company dedicated to the provision of specialized services to the pharmaceutical industry and the development of new drugs, announced the strengthening of its executive team with the appointment of Dr. Dan Weng as its new chief executive officer and a board director of Ergomed. Dr. Weng joins Ergomed with effect from 1 July 2017 from EPS Holdings (EPSHD), a global CRO listed on the Tokyo Stock Exchange.

When Dr. Weng joins the company, Dr. Miroslav Reljanovic, Ergomed’s founder, will transition from CEO to executive vice-chairman, where he will support Dr. Weng and the board in growing and developing Ergomed’s CRO offering and provide strategic guidance on Ergomed’s co-development business and wholly-owned pipeline.

Dr. Weng has extensive experience in managing and growing CRO businesses, including nearly six years at EPS International Holding (EPSI), subsidiary of EPSHD, where he was chairman, president and CEO. During his tenure at EPSI, Dr. Weng oversaw significant growth, both organically and through M&A in Asia, the U.S. and Europe, with revenues increasing over five-fold. Dr. Weng’s background covers multiple therapeutic areas, supporting all stages of development through to approval. He was also a board director of EPSHD and had an active role in corporate strategy and investor relations.

Prior to this, Dr. Weng has a proven track record with 20 years of delivering growth in executive positions at international CROs including MedPace, Icon Clinical Research, PharmaNet and Quintiles, where he established the offering in China.

Dr. Weng qualified as a medical doctor at Tongji Medical University, China, and holds an MA in Health Planning, Policy and Management from the University of Leeds, U.K. He also held research positions at Harvard Medical School, Massachusetts General Hospital and the University of California.

Reljanovic said: “Ergomed has a history of innovation in clinical research and development and this is set to continue. I’m very pleased to welcome Dan to the team to guide Ergomed forward as we seek to build on the strong growth of our CRO and pharmacovigilance businesses. I look forward to contributing to Ergomed’s continued success as Vice-Chairman, focusing on our existing and future co- development deals, our pipeline products, and the broader strategy of the business.”

Peter George, chairman of Ergomed, said: “Dan has significant experience in growing CRO businesses globally, and is an ideal addition to the Ergomed team. With the increasing maturity and scale of the business, his international experience in corporate development across all the areas of clinical research make for an excellent fit.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing